Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.
Shah
P K
PK
Atherosclerosis Research Center, Division of Cardiology, Burns and Allen research Institute, Los Angeles, California, USA. shahp@cshs.org
Kaul
S
S
Nilsson
J
J
Cercek
B
B
D000818:Animals; D016632:Apolipoprotein A-I / Q000097:blood; D001053:Apolipoproteins / Q000097:blood / Q000494:pharmacology*; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D001692:Biological Transport; D004730:Endothelium, Vascular / Q000187:drug effects; D005342:Fibrinolysis / Q000187:drug effects; D015438:Health Behavior; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications; D007249:Inflammation / Q000517:prevention & control; D008075:Lipoproteins, HDL / Q000097:blood / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000009:adverse effects / Q000097:blood; D008244:Lysophosphatidylcholines / Q000037:antagonists & inhibitors / Q000378:metabolism; D010084:Oxidation-Reduction; D013927:Thrombosis / Q000517:prevention & control
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines